Clinical and Biochemical Diagnosis in Children with Leigh Syndrome by 源��꽭�썕 et al.
대한 유전성 대사 질환 : 2015;15(2):72~77 원     저
- 72 -
Leigh 증후군 환자의 임상적 생화학적 진단
연세대학교 의과대학 소아청소년과
1, 고잔 연세 소아청소년과
2, 연세대학교 의과대학 병리과
3
이선호1ㆍ전미나1ㆍ이현주1ㆍ박대영2ㆍ김세훈3ㆍ이영목1
Clinical and Biochemical Diagnosis in Children with Leigh Syndrome
Sun Ho Lee, M.D.
1
, Mina Jeon, M.D.
1
, Hyun Joo Lee, M.D.
1
, Dae Young Park, M.D.
2
Se Hoon Kim, M.D., Ph.D.
3
, Young-Mock Lee, M.D., Ph.D.
1
Departments of Pediatrics1, Yonsei University College of Medicine, Seoul, Korea
Kojan Yonsei Pediatric Clinic2, Ansan, Korea
Departments of Pathology
3
, Yonsei University College of Medicine, Seoul, Korea
Purpose: Deficits of the respiratory chain are reported to be the major cause of Leigh syndrome is said 
to be the underlying causes. The need for biochemical diagnosis to draw more accurate diagnosis or 
prognosis to support treatments is rapidly increasing. This study tried to analyze the aspects of clinical 
characteristics and biochemical diagnosis of mitochondrial respiratory chain complex (MRC) defect in 
Leigh syndrome, using methods of biochemical enzyme assay. 
Methods: We included total number of 47 patients who satisfied the clinical criteria of Leigh syndrome 
and confirmed by biochemical diagnosis. All those patients went through muscle biopsy to perform bio-
chemical enzyme assay to analyze MRC enzyme in order to find the underlying cause of Leigh syndrome. 
Results: MRC I defect was seen in 23 (48.9%) cases taking the first place and MRC IV defect in 15 
(31.9%) following it. There were 9 (19.2%) cases of combined MRC defect. Combined cases of type 
I and IV were detected in 7 (14.9%) patients while type I and V in 2 (4.3%). The onset age of symptom 
was less than 1 year old in 28 (59.6%). The most common early symptom, observed in 23 (48.9%), 
was delayed development, but there were other various neurological symptoms observed as well. In 
regard with the disease progression, 35 (74.5%) patients showed slowly progressive course, the one 
that progressed continuously but slowly over 2 years of period. As for Maximum motor development, 
22 (46.8%) were bed-ridden state, most of them suffering serious delayed development. Patients showed 
various symptoms with different organs involved, though neuromuscular involvement was most prominent. 
Delayed development was seen in all cases. Multifocal lesion in brain MRI study was seen in 36 (76.6 
%) cases, taking a greater percentage than 11 (23.4%) cases with single lesion. In MR spectroscopy 
study, the characteristic lactate peak of mitochondrial disease was identified in 20 (42.6%) patients.
Conclusions: Further analysis of clinical and biochemical diagnosis on more extended group of patients 
with Leigh syndrome will enable us to improve diagnostic precision and to understand the natural course 
of mitochondrial disease. 
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Introduction
Leigh syndrome is known as the most repre-
sentative mitochondrial disease involving abnormal 
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energy production. It shows characteristic lesion 
in the brain, especially in areas such as the basal 
ganglia, diencephalon, cerebellum, or brainstem 
and clinically takes a progressive natural course 
1, 2). Leigh syndrome generally starts during in-
fancy or early childhood. Most are fatal cases and 
patients usually expire before the age of 5 years 
old. Clinically, progressive decline of central ner-
vous system function is the most crucial symptom 
involved3, 4). But other various symptoms like psy-
chomotor delay, weakness, hypotonia, and ataxia 
et al. are not difficult to observe, either. Organ 
involvement other than neuromuscular system 
occurs as well5, 6).
Deficits of the respiratory chain, coenzyme Q, 
or the pyruvate dehydrogenase complex are re-
ported to be the cause of Leigh syndrome, and 
mutations of the genes encoding subunits of the 
respiratory chain or assembly factors of respira-
tory chain complexes are said to be the under-
lying cause7). Thus, biochemical enzyme assay en-
ables one to confirm the cause in Leigh syndrome. 
Nonetheless, it is practically very difficult to 
find thoroughly all those kinds of clinical charac-
teristics and biochemical abnormalities in every 
patient suspected of having Leigh syndrome. And 
even if one did, the results can sometimes be dis-
cordant8). Till today, diagnosing Leigh syndrome 
is done mainly based on its characteristic clinical 
symptoms and neuroimaging studies. The need 
for biochemical diagnosis to draw more accurate 
diagnosis or prognosis to support treatments is 
rapidly increasing. This study tried to analyze the 
aspects of clinical characteristics and biochemical 
diagnosis of mitochondrial respiratory chain com-
plex (MRC) defect, the most widely known cause 
of Leigh syndrome, using methods of biochemical 
enzyme assay.
Materials and Methods
We included total number of 47 patients who 
had visited the pediatric neurology department in 
Gangnam Severance Hospital and Severance Chil-
dren’s Hospital between March 2010 and De-
cember 2014 and who satisfied the clinical criteria 
of Leigh syndrome retrospectively. Clinical criteria 
of Leigh syndrome are as following: (1) progres-
sive neurological disease with motor and intellec-
tual developmental delay; (2) signs and symptoms 
of brainstem and/or basal ganglia disease; (3) 
raised lactate levels in blood and/or cerebrospinal 
fluid (CSF); and (4) one or more of the following: 
(a) characteristic features of Leigh syndrome on 
neuroimaging (symmetrical hypodensities in the 
basal ganglia on computed tomography or hyper-
intense lesions on T’2-weighted magnetic re-
sonance imaging (MRI), (b) typical neuropatholo-
gical changes at postmortem, or (c) typical neu-
ropathology in a similarly affected sibling9). All 
those 47 patients went through muscle biopsy to 
perform biochemical enzyme assay to analyze MRC 
enzyme in order to find the underlying cause of 
Leigh syndrome. 
Skeletal muscle was assayed by modifications 
of published methods and sample preparation was 
done at 0 to 4℃10-12). Respiratory chain enzymes 
were assayed at 30℃ using a spectrophotometer 
on the same day that the tissue was homogenized. 
Evaluation of MRC dysfunction was performed by 
analyzing the activities of reduced nicotinamide 
adenine dinucleotide-coenzyme Q (CoQ) reductase 
(complex I), succinate-CoQ reductase (complex 
II), succinatecytochrome c reductase (complexes 
II-III), cytochrome c reductase (complex III), 
cytochrome c oxidase (complex IV), oligomycin- 
- 대한 유전성 대사 질환 : 제 15권 제 2호, pp72~77, 2015 -
- 74 -
Table 1. Results of Biochemical Enzyme Assay for MRC 
(N=47)
MRC function  No. of patients (%)
Abnormal
 
 
 
Total
I defect
IV defect
I+IV defect
I+V defect
 
23 (48.9)
15 (31.9)
 7 (14.9)
 2 (4.3)
47 (100.0)
Table 2. Clinical Characteristics of Leigh Syndrome Pa-
tients with MRC Defect (N=47)
Characteristics  
No. of 
patients (%)
Symptom onset
 age (years)
 
 
 Initial symptom
 
 
 
 
 
 
Disease course
 
 
 
Maximum motor 
 development
 
 
 
Continuous 
 ventilator care
Expire cases
Abnormal family 
 history
Birth history
 
 
 
Neonate
>1 month, =<1 year
>1 year, =<5 years
>5 years
Delayed development
Seizure
Hypotonia
Ataxia
Ptosis
Lethargy
Spasticity
Fulminant
Rapidly progressive
Slowly progressive
Chronic stable
Bed-ridden
Sitting
Standing
Walking by support
Incomplete gait
 
 
 
Prematurity
Low birth weight
Severe asphyxia
Mild asphyxia
 3 (6.4)
25 (53.2)
17 (36.2)
 2 (4.2)
23 (48.9)
10 (21.3)
 5 (10.6)
 4 (8.5)
 2 (4.2)
 2 (4.2)
 1 (2.1)
 2 (4.2)
 3 (6.4)
35 (74.5)
 7 (14.9)
22 (46.8)
 3 (6.4)
 2 (4.2)
 7 (14.9)
13 (27.8)
15 (31.9)
 7 (14.9)
 9 (19.1)
 6 (12.8)
 9 (19.1)
 3 (6.4)
 9 (19.1)
sensitive ATPase (complex V) and citrate syn-
thase assessed from isolated mitochondria in mu-
scle tissue through use of standard spectrophoto-
metric assays as described by Rustin et al12). We 
defined an MRC defect as reduction of residual 
enzyme activity below 20% of controls.
Results
1. Biochemical enzyme assay of MRC (Table 1)
Most cases, 38 (80.9%) to be exact, had single 
MRC defect. MRC I defect was seen in 23 (48.9 
%) cases taking the first place and MRC IV de-
fect in 15 (31.9%) following it. There were 9 
(19.1%) cases of combined MRC defect. Combined 
cases of type I and IV were detected in 7 (14.9 
%) patients while type I and V in 2 (4.3%).
2. Cilinical characteristics of Leigh syndrome 
   patients with MRC defect (Table 2)
Sex ratio of 47 patients with MRC defect in 
biochemical enzyme assay was 1.14:1. The onset 
age of symptom was less than 1 year old in 28 
(59.6%), neonatal period in 3 (6.4%), and after 5 
years of age in 2 (4.2%) cases. The most com-
mon early symptom, observed in 23 (48.9%), was 
delayed development, but there were other various 
neurological symptoms observed as well. In re-
gard with the disease progression, 2 (4.2%) pa-
tients followed fulminant course which lead to 
expire within 6 months of initial presentation. 
Three (6.4%) followed rapidly progressive course 
which showed rapid deterioration that brought 
expire within 2 years, and 35 (74.5%) showed 
slowly progressive course, the one that progressed 
continuously but slowly over 2 years of period. 
There were 7 (14.9%) patients who followed 
chronic stable course besides them13). There were 
7 (14.9%) expire cases and 15 (31.9%) which 
needed continuous ventilator care. As for Maxi-
mum motor development, 22 (46.8%) were bed- 
ridden state, most of them suffering serious de-
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Table 4. Brain MRI and MR spectroscopy findings in 
Leigh syndrome patients with MRC defect 
(N=47)
Location of abnormalities No. of patients (%)
Involvement pattern
Multiple lesions
  Single lesion
MRI
Basal ganglia
Diffuse cerebral atrophy
Brain stem
Cerebellum
Thalamus
MR spectroscopy 
  Lactate peak
 
36 (76.6)
11 (23.4)
 
47 (100.0)
25 (53.2)
19 (40.4)
11 (23.4)
19 (40.4)
 
20 (42.6)
Table 3. Clinical Features of Organ Involvement in 
Leigh Syndrome Patients with MRC Defect 
(N=47)
Clinical features  
No. of 
patients (%)
Developmental delay
Hypotonia
 
 
Spasticity
 
 
Dystonia
Involuntary movement
Ataxia
Seizure
Ocular symptom
 
 
 
 
 
Poor feeding
 
 
Unexpected vomiting
Levin tube feeding
Gastrostomy feeding
Failure to thrive
 
 
Hepatic involvement
Cardiac involvement
Renal involvement
Respiratory problem
Auditory involvement
 
Severe
Moderate
Mild
Severe
Moderate
Mild
 
 
 
 
Optic atrophy
Retinopathy
Nystagmus
Ophthalmoplegia
Ptosis
Strabismus
Severe
Moderate
Mild
 
 
 
Severe
Moderate
Mild
 
 
 
 
 
47 (100.0)
19 (40.4)
 6 (12.8)
11 (23.4)
 8 (17.0)
 5 (10.6)
13 (27.7)
 9 (19.1)
22 (46.8)
15 (31.9)
29 (61.7)
 2 (4.2)
 7 (14.9)
14 (29.8)
 7 (14.9)
 5 (10.6)
 5 (10.6)
17 (36.1)
10 (21.3)
 9 (19.1)
38 (80.9)
18 (38.3)
 6 (12.8)
18 (38.3)
 8 (17.0)
11 (23.4)
 7 (14.9)
11 (23.4)
 3 (6.4)
17 (36.1)
 5 (10.6)
layed development. There were 12 (25.5) with 
the birth history of asphyxia.
3. The clinical features of organ involvement 
   in Leigh syndrome patients with MRC defect 
   (Table 3)
Patients showed various symptoms with diffe-
rent organs involved, though neuromuscular invol-
vement was most prominent. Delayed development 
was seen in all cases. Hypotonia was seen in 36 
(76.6%) patients and spasticity in 2 6 (55.3%). 
Twenty nine (61.7%) had seizure episodes while 
involuntary movement (46.8%), ataxia (31.9%), 
and dystonia (19.1%) were reported as well. Ny-
stagmus was the most common ophthalmologic 
finding, noted in 14 (29.8%) patients. Ophthalmo-
plegia (14.9%), retinopathy (14.9%), ptosis (10.6 
%), and strabismus (10.6%) were seen in others. 
Problems related with oral intake and failure to 
thrive was also observed. Poor feeding was seen 
in 36 (76.6%) and unexpected vomiting in 38 
(80.9%) patients. Among them, 18 (38.3%) re-
quired continuous Levin tube feeding and 6 (12.8 
%) even required gastrostomy feeding. Respiratory 
problem appeared in 17 (36.1%) cases. Cardiac 
involvements were seen in 11 (23.4%) cases. 
Hepatic, renal, and auditory system involvements 
were also observed.
4. Brain MRI and MR spectroscopy findings
   in Leigh syndrome patients with MRC 
   defect (Table 4)
Multifocal lesion in brain MRI study was seen 
in 36 (76.6%) cases, taking a greater percentage 
than 11 (23.4%) cases with single lesion. Basal 
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ganglia lesion was observed in all patients. Diffuse 
atrophy was seen in 25 (53.2%) cases. Brain stem 
and thalamus lesion was seen in 19 (40.4%) pa-
tients respectively. In MR spectroscopy study, 
the characteristic lactate peak of mitochondrial 
disease was identified in 20 (42.6%) patients.
Discussion
Leigh syndrome is associated with heteroge-
neous, biochemical abnormalities in the mitochon-
dria of the skeletal muscle, detectable in about 
50% of affected patients6, 14, 15). This certainly 
implies the difficulty of diagnosing mitochondrial 
diseases. However, like other clinical syndromes 
that later get classified as specific diseases after 
their exact pathogenesis are understood and more 
definite diagnostic criteria are introduced, mito-
chondrial disorder is taking the similar path from 
being diagnosed clinical criteria by biochemical 
methods. The study results that we obtained show 
quite similar rates of diagnosis with those of pre-
viously reported biochemical diagnosis16, 17). These 
sophisticated types of diagnostic tools could sup-
port in predicting disease progression and prog-
nosis, thus enable us to make a better judgment 
on treatments provided. No need to say that their 
assistance will be more needed in the future.
The natural course of Leigh syndrome has us-
ually been characterized as sudden progressive 
neurological symptoms leading to early expire in 
many cases5, 6). Interestingly, during our study 
many patients rather seem to take a slow progres-
sive course of a degenerative disease. It seems 
that the recent increased attentions on mitochon-
drial disorder have made improvements in the 
diagnostic skills and facilitated to make earlier 
diagnosis. Although no causal treatment is avail-
able for Leigh syndrome generally, the introduc-
tions of various possible drugs and improved ge-
neral treatment should also be considered as the 
reason for the difference in the disease course. 
The patients we included in the study were con-
tinuously treated with drugs such coenzyme-Q, 
L-carnitine, and vitamins and checked for other 
organ involvement after being diagnosed5, 18, 19). 
Close monitoring of patients with respiratory dis-
turbances, and the application of tests to assess 
brainstem function may prevent sudden death in 
early-onset Leigh syndrome20).
There have been studies analyzing clinical 
symptoms based on biochemical diagnosis, but 
most were done with limited number of cases. 
Few were related with specific mitochondrial 
disease group such as Leigh syndrome. Previous 
reports had stated that no certain objective cor-
relation between clinical symptoms and abnor-
malities in biochemical assay was observed21). 
The weakness of this study is that we did not 
study all the genes known to cause Leigh synd-
rome. Further gene analysis on more extended 
group of patients with Leigh syndrome will enable 
us not only to improve diagnostic precision but to 
understand mitochondrial disease one step further 
as well by revealing the correlation between its 
phenotypes and genotypes. 
It is still rather a challenging work to diagnose 
and evaluate mitochondrial diseases precisely. 
However, sophisticated types of diagnostic tools 
such as biochemical enzyme assay and molecular 
analysis could give us a hand in predicting disease 
progression and prognosis, and enable us to make 
better choices when treating a patient. 
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